Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis
| Autor: | Anand Devaraj, Joseph Jacob, Andre Altmann, Ronald A. Karwoski, Eoin P. Judge, Angelo De Lauretis, Hendrik W. van Es, Teresa Burd, Maria Kokosi, Ryan Clay, Elisabetta A. Renzoni, Teng Moua, Srinivasan Rajagopalan, Tobias Peikert, Frouke T. van Beek, Marcel Veltkamp, Brian J. Bartholmai, Toby M. Maher, Coline H.M. van Moorsel, Athol U. Wells, Fabien Maldonado |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Vital Capacity Respiratory System Pattern Recognition Automated 03 medical and health sciences FEV1/FVC ratio Idiopathic pulmonary fibrosis 0302 clinical medicine Critical Care Medicine Longitudinal prediction General & Internal Medicine Internal medicine Image Processing Computer-Assisted medicine Humans 030212 general & internal medicine Agora 11 Medical and Health Sciences Proportional Hazards Models Science & Technology Proportional hazards model business.industry Confounding Ct analysis respiratory system medicine.disease Research Letters Idiopathic Pulmonary Fibrosis Outcome (probability) 3. Good health respiratory tract diseases Treatment Outcome 030228 respiratory system Cohort Linear Models sense organs Tomography X-Ray Computed business Life Sciences & Biomedicine |
| Zdroj: | The European Respiratory Journal |
| DOI: | 10.1101/493544 |
| Popis: | The advent of antifibrotic agents [1, 2] as standard of care in idiopathic pulmonary fibrosis (IPF) requires that new non-inferiority IPF drug trials will need to identify smaller declines of forced vital capacity (FVC). Marginal annualised FVC declines (between 5.00 and 9.99%) are particularly challenging to interpret as they might reflect measurement variation or genuine clinical deterioration [3]. Following on from previous baseline-only computed tomography (CT) analyses [4], the current study examined whether changes in computer features (CALIPER) across serial CT examinations could be considered as a trial co-endpoint, particularly with regard to adjudicating marginal FVC declines, and therefore improve the sensitivity of IPF drug trials. Change in the vessel-related structures, a computer-derived CT variable, is a strong predictor of outcome in idiopathic pulmonary fibrosis and can increase power in future drug trials when used as a co-endpoint alongside forced vital capacity change http://bit.ly/2M7DfKS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|